Filing Flows

Filing Flows › Companies › Supernus Pharmaceuticals › Cash flow

Supernus Pharmaceuticals cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$6.4M in Q3 2026 · $87.0M over twelve months

Operating cash flow$6.6M
Capital spending−$230K
Free cash flow+$6.4M
Cash / net income0.3×
Cash conversion cycle437 days

Analysis

In Q3 2026, Supernus Pharmaceuticals generated $6.6M of operating cash flow and spent $230K on capital projects, leaving free cash flow of $6.4M. That is $68.2M more than in Q3 2025 (−$61.8M).

Over the twelve months to Sep 30, 2026, operating cash flow was $88.2M; the largest uses were other investing ($54.5M), other financing ($31.2M), taxes on employees’ shares ($5.5M); besides operations, cash came from shares issued ($28.7M); the cash balance rose by $24.5M.

Operating cash flow was $6.6M against net income of $20.9M — 0.3× profit, less cash than reported earnings, worth checking against working capital. The largest differences: depreciation & amortization +$23.6M, inventory −$10.5M, stock-based pay +$8.9M.

Its cash conversion cycle was 437 days (receivables 86 + inventory 375 − payables 24).

Free cash flow

Supernus Pharmaceuticals: free cash flow by quarterSupernus Pharmaceuticals: free cash flow by quarter$44.2MQ4 2024$30.3MQ1 2025$58.1MQ2 2025−$61.8MQ3 2025$19.4MQ4 2025$66.5MQ1 2026−$5.4MQ2 2026$6.4MQ3 2026
Operating cash flow less capital spending.
Supernus Pharmaceuticals: operating cash flow against capital spendingSupernus Pharmaceuticals: operating cash flow against capital spendingOperating cash flowCapital spending$44.4M$213KQ4 2024$30.6M$327KQ1 2025$58.5M$455KQ2 2025−$61.7M$129KQ3 2025$19.9M$427KQ4 2025$66.5M$0Q1 2026−$4.8M$568KQ2 2026$6.6M$230KQ3 2026
Latest (Q3 2026): Operating cash flow $6.6M, Capital spending $230K.

Capital allocation, year by year

Supernus Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearSupernus Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsFY2021: Operating cash flow $127MFY2021: Shares issued $7.1MFY2021: Asset sales $12.9MFY2021: Acquisitions −$950K$147MFY2021FY2022: Operating cash flow $117MFY2022: Shares issued $22.8MFY2022: Capital spending −$412K$140MFY2022FY2023: Operating cash flow $111MFY2023: Net borrowing −$402MFY2023: Shares issued $10.9MFY2023: Capital spending −$551K$122MFY2023FY2024: Operating cash flow $172MFY2024: Shares issued $21.7MFY2024: Capital spending −$725K$194MFY2024FY2025: Operating cash flow $47.3MFY2025: Shares issued $72.5MFY2025: Capital spending −$1.3MFY2025: Acquisitions −$293M$120MFY2025
Over these 5 years operating cash flow totalled $574M; the largest uses were net borrowing ($402M) and acquisitions ($294M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$176M
Debtnone
Net cash$176M

Supernus Pharmaceuticals funds itself: free cash flow was $87.0M over the last twelve months, with $176M of cash and investments and no debt on the balance sheet.

Where the cash came from and went

Supernus Pharmaceuticals: sources (+) and uses (−) of cash, Q3 2026Supernus Pharmaceuticals: sources (+) and uses (−) of cash, Q3 2026Other financing−$19.9MOther investing$8.0MOperating cash flow$6.6MCash drawn (+) / kept (−)$4.1MShares issued$2.3MTaxes on employees’ shares−$787KCapital spending−$230K
Supernus Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q3 2026Supernus Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow$88.2MOther investing−$54.5MOther financing−$31.2MShares issued$28.7MCash drawn (+) / kept (−)−$24.5MTaxes on employees’ shares−$5.5MCapital spending−$1.2M

From profit to cash

Supernus Pharmaceuticals: net income to operating cash flow, Q3 2026Supernus Pharmaceuticals: net income to operating cash flow, Q3 2026Net income$20.9MDepreciation & amortization$23.6MStock-based pay$8.9MDeferred taxes−$5.3MImpairments$1.5MOther non-cash$349KReceivables−$3.1MInventory−$10.5MPayables−$3.8MPrepaid and other assets$6.3MOperating cash flow$6.6M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 20268637524437
Q2 20268229421355
Q1 20268042925485
Q4 20257843922495
Q3 20257536740402
Q2 20257925341290
Q1 20258629633349
Q4 20247620819265

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$6.6M−$230K$2.3M$4.1M$6.4M
Q2 2026−$4.8M−$568K$4.1M$4.9M−$5.4M
Q1 2026$66.5M—$13.7M−$56.4M$66.5M
Q4 2025$19.9M−$427K$8.6M$22.9M$19.4M
Q3 2025−$61.7M−$129K$23.7M−$8.1M−$61.8M
Q2 2025$58.5M−$455K$3.3M−$28.9M$58.1M
Q1 2025$30.6M−$327K$2.0M−$46.5M$30.3M
Q4 2024$44.4M−$213K$6.9M−$37.7M$44.2M

Supernus Pharmaceuticals: income statement and cash flow

Supernus Pharmaceuticals, Q3 2026: revenue $227M (+18% year over year), operating margin 9.3%. The chart follows the revenue to costs, profit and cash.

Supernus Pharmaceuticals: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.